Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients

Journal of Microbiology, Immunology and Infection

Volumn 44, Issue 1, 2011, Pages 45-51

  Kuo, Shu Chen ^a,b   Wang, Fu Der ^a,b   Fung, Chang Phone ^a,b   Chen, Liang Yu ^a   Chen, Su Jung ^a,b   Chiang, Mei Chun ^a   Hsu, Shih Fen ^a   Liu, Cheng Yi ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Acinetobacter baumannii; Multidrug resistant; Tigecycline; Ventilator associated pneumonia

Indexed keywords

CEFEPIME; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULTAMICILLIN; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ACINETOBACTER INFECTION; ADULT; AGED; ARTICLE; BACTEREMIA; CRITICALLY ILL PATIENT; FEMALE; GERIATRIC PATIENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OSTEOMYELITIS; RETROSPECTIVE STUDY; TAIWAN; TREATMENT OUTCOME; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; CRITICAL ILLNESS; DRUG EFFECTS; MIDDLE AGED; OFF LABEL DRUG USE; PNEUMONIA, VENTILATOR-ASSOCIATED; VERY ELDERLY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; HUMANS; MIDDLE AGED; MINOCYCLINE; OFF-LABEL USE; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; TAIWAN; TREATMENT OUTCOME;

EID: 79952248676     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.01.009     Document Type: Article

References (22)

1. Pankey G.A. Tigecycline. J Antimicrob Chemother 2005, 56:470-480.
2. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., Testa R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999, 43:738-744.
3. Souli M., Kontopidou F.V., Koratzanis E., Antoniadou A., Giannitsioti E., Evangelopoulou P., et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006, 50:3166-3169.
4. Anthony K.B., Fishman N.O., Linkin D.R., Gasink L.B., Edelstein P.H., Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008, 46:567-570.
5. Song J.Y., Kee S.Y., Hwang I.S., Seo Y.B., Jeong H.W., Kim W.J., et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007, 60:317-322.
6. Lolans K., Rice T.W., Munoz-Price L.S., Quinn J.P. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006, 50:2941-2945.
7. Joly-Guillou M.L. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005, 11:868-873.
8. Karageorgopoulos D.E., Falagas M.E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008, 8:751-762.
9. Karageorgopoulos D.E., Kelesidis T., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008, 62:45-55.
10. Munoz-Price L.S., Weinstein R.A. Acinetobacter infection. N Engl J Med 2008, 358:1271-1281.
11. Schafer J.J., Goff D.A., Stevenson K.B., Mangino J.E. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007, 27:980-987.
12. Cainzos M. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections-are they applicable today?. Clin Microbiol Infect 2008, 14(Suppl. 6):S9-18.
13. Guidelines for antimicrobial therapy of intra-abdominal infections in adults. J Microbiol Immunol Infect 2008, 41:279-281. Infectious Diseases Society of Taiwan; Taiwan Surgical Society of Gastroenterology; Medical Foundation in Memory of Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines.
14. Curcio D., Fernandez F., Cane A., Barcelona L., Stamboulian D. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis 2008, 12:198-201.
15. Valles J., Leon C., Alvarez-Lerma F. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Spanish Collaborative Group for Infections in Intensive Care Units of Sociedad Espanola de Medicina Intensiva y Unidades Coronarias (SEMIUC). Clin Infect Dis 1997, 24:387-395.
16. Falagas M.E., Bliziotis I.A., Siempos I.I. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006, 10:R48.
17. Gallagher J.C., Rouse H.M. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 2008, 42:1188-1194.
18. Falagas M.E., Rafailidis P.I. Attributable mortality of Acinetobacter baumannii: no longer a controversial issue. Crit Care 2007, 11:134.
19. Meagher A.K., Ambrose P.G., Grasela T.H., Ellis-Grosse E.J. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005, 52:165-171.
20. Scheetz M.H., Qi C., Warren J.R., Postelnick M.J., Zembower T., Obias A., et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51:1621-1626.
21. Peleg A.Y., Potoski B.A., Rea R., Adams J., Sethi J., Capitano B., et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007, 59:128-131.
22. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl. 5):S341-S353. Tigecycline 300 cSSSI Study Group.